Coronavirus Infections Clinical Trial
Official title:
Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement
This is a prospective observational cohort study that will define the prevalence and incidence of CA-SARS-Cov2 infection using serological and PCR tests in a group of subjects during deconfinement. The team wishes to include approximately 1000 subjects in this study. The health crisis through containment has also created unprecedented environmental conditions with the very clear decrease in economic activities and a consequent decrease in exposure to the main air pollutants. The aim is therefore to carry out a case-control study in which each subject will be his or her own control in unexposed condition (to PM2.5, PM10, NO...) then exposed (after the recovery of economic activity and the usual levels of air pollutants) and to measure the impact of these pollutants on the immune system and epigenetic markers taking into account seasonality. The occurrence of infectious, cardiovascular, allergic and autoimmune events will then be measured according to the immunological profiles measured at inclusion.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04553575 -
CoViD-19 Patient in Reims University Hospital in March to April 2020
|
||
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Active, not recruiting |
NCT05548439 -
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
|
Phase 1 | |
Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05726084 -
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
|
Phase 2/Phase 3 | |
Recruiting |
NCT05069129 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
Recruiting |
NCT05599516 -
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
|
Phase 3 | |
Completed |
NCT05047900 -
The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community
|
N/A | |
Completed |
NCT04420286 -
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
|
||
Completed |
NCT04424355 -
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
|
||
Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
Enrolling by invitation |
NCT04327349 -
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
|
N/A | |
Completed |
NCT04321278 -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
|
Phase 3 | |
Recruiting |
NCT04327570 -
In-depth Immunological Investigation of COVID-19.
|
||
Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
Recruiting |
NCT04322344 -
Escin in Patients With Covid-19 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Completed |
NCT04323592 -
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
|